Profile
BLCM NVO VRTX REGN SGEN MRNA
Company Name Bellicum Pharmaceuticals, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Moderna, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $778.33K $550.22B $102.67B $95.34B $43.15B $41.34B
Employees 0.01K 63.37K 5.40K 13.45K 3.26K 5.60K
CEO Mr. David M. Maggio Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Stephane Bancel
Ratings
BLCM NVO VRTX REGN SGEN MRNA
Quant Rating Score 3 5 5 5 3 4
Quant Rating Neutral Strong Buy Strong Buy Strong Buy Neutral Buy
Trading
BLCM NVO VRTX REGN SGEN MRNA
Last Close $0.07475 $126.85 $397.48 $883.2 $228.74 $107.97
High 52 $0.96 $199.54 $446.08 $993.35 $228.9 $137.75
Low 52 $0.07 $87.78 $323.57 $692.45 $187.64 $69.51
Price vs. 52 Week High -92.21 % -36.43 % -10.89 % -11.09 % -0.07 % -21.62 %
Price vs. 52 Week Low 6.79 % 44.51 % 22.84 % 27.55 % 21.9 % 55.33 %
Total Return
BLCM NVO VRTX REGN SGEN MRNA
1 Month Return 0 % -1.21 % -4.91 % -8.24 % 0 % 1.32 %
3 Month Return -6.56 % 16.35 % -8.8 % -7.6 % 0 % 2.99 %
6 Month Return -58.47 % 35.67 % 11.88 % 13.93 % 6.59 % 50.15 %
9 Month Return -83.75 % -19.62 % 12.27 % 18.38 % 19.07 % -9.01 %
YTD Return -50.17 % 22.62 % -2.31 % 0.56 % 0 % 8.57 %
1 Year Return -78.64 % -24.08 % 16.66 % 10.15 % 14.37 % -18.75 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
BLCM NVO VRTX REGN SGEN MRNA
Dividend Yield Percentage (TTM) - 1.43 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -2077.27 % 1.54 % 13.69 % 5.88 % -3.35 % -4.41 %
Dividend Per Share (TTM) - 1.81 % - - - -
Payout Ratio (TTM) - 37.96 % - - - -
Growth
BLCM NVO VRTX REGN SGEN MRNA
Asset Growth -51.52 % 30.35 % 25.23 % 13.23 % -1.21 % -28.74 %
Gross Profit Growth -75.81 % 32.32 % 9.25 % 6.49 % 22.93 % -85.12 %
Revenue Growth -75.81 % 31.26 % 10.17 % 7.76 % 24.65 % -64.94 %
Revenue 3 Year -96.81 % 90.51 % 59.87 % 56.27 % 91.84 % 2354.12 %
Revenue 5 Year -16.59 % 124.2 % 218.58 % 97.36 % 215.48 % 1070.62 %
Revenue 10 Year -96.75 % 66.11 % 608.27 % 509.63 % 494.04 % 6447.35 %
EBIT Growth -8.51 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Net Income Growth -160.73 % 50.71 % 8.96 % -8.87 % 9.51 % -156.37 %
Net Income 3 Yeari Growth Per Share 96.99 % 106.79 % 34.59 % 13.92 % -764.83 % -529.35 %
Net Income 5 Yeari Growth Per Share 97.2 % 133.86 % 70.33 % 63.31 % -276.93 % -160.17 %
Net Income 10 Yeari Growth Per Share 87.29 % 98.61 % 809.6 % 811.34 % -624.16 % -2046.03 %
Operating Income Growth -8.51 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Operating Cash Flow Growth (CFG) -11.59 % 38.06 % -14.35 % -8.39 % 9.07 % -162.6 %
Operating 3 Year CFG 94.95 % 118.29 % 9.63 % 77.63 % -148.34 % -253.42 %
Operating 5 Year CFG 96.37 % 163.51 % 174.78 % 111.31 % -195.86 % -100.11 %
Operating 10 Year CFG 89.39 % 150.92 % 5187.08 % 663.48 % -2622.09 % -4698.89 %
EPS Growth 2.41 % 52.28 % 8.33 % -8.54 % 10.81 % -158.04 %
EPS Diluted Growth 2.41 % 52.37 % 8.35 % -9.03 % 10.81 % -161.33 %
Book Value Per Share -96.92 % 29 % 25.58 % 14.4 % -9.83 % -21.18 %
Share Holder 3 Year Equity Growth Per Share 101.17 % 75.22 % 104.06 % 138.48 % 33.92 % 439.47 %
Share Holder 5 Year Equity Growth Per Share -99.76 % 121.9 % 291.14 % 199.46 % 220.81 % 92.24 %
Share Holder 10 Year Equity Growth Per Share 100.33 % 49.62 % 1030.79 % 1201.51 % 691.19 % 1519.81 %
Dividend Per Share Growth - 26.89 % - - - 59.65 %
Dividend 3 Year Growth Per Share - 64.4 % -100 % - - 3725.19 %
Dividend 5 Year Growth Per Share - 80.03 % -100 % - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth - 4.74 % 44.1 % 0.06 % -23.28 % 3.58 %
Free Cash Flow Growth -11.64 % 9.17 % -16.47 % -17.11 % 3.67 % -183.5 %
Updated On 31 Dec 2022 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
BLCM NVO VRTX REGN SGEN MRNA
Gross Profit Margin TTM 100 % 84.6 % 87.21 % 87.87 % 75.4 % 31.49 %
Return on Assets TTM -318.07 % 26.61 % 15.92 % 11.95 % -20.64 % -25.58 %
Return on Equity TTM 153.34 % 90.49 % 22.62 % 16.07 % -28.06 % -29.87 %
Return on Capital Employed TTM -500.72 % 70.82 % 19.82 % 13.65 % -29.5 % -27.51 %
Net Income Per EBT TTM 97.41 % 79.95 % 82.64 % 94.15 % 101.53 % 119.58 %
EBT Per Ebit TTM 97.06 % 102.05 % 115.19 % 103.76 % 93.47 % 92.99 %
EBIT Per Revenue TTM -1528.71 % 44.16 % 38.53 % 30.85 % -34.37 % -61.88 %
Cash Flow To Debt Ratio TTM - 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Receivables Turnover TTM 100.53 3.09 6.31 2.31 3.64 6.34
Payables Turnover TTM - 1.4 3.46 2.62 2.52 9.03
Inventory Turnover TTM - 1.12 1.71 0.62 1.07 23.23
Fixed Asset Turnover TTM 30160 % 255.34 % 679.28 % 316.35 % 471.71 % 257.71 %
Asset Turnover TTM 22 % 73.85 % 43.42 % 39.65 % 63.3 % 37.18 %
Operating Cash Flow Per Share TTM -0.74 24.39 13.73 43.1 -2.87 -8.18
Free Cash Flow Per Share TTM -0.74 15.68 12.72 35.77 -3.73 -10.04
Cash Per Share TTM 19.12 % 677.09 % 4354.48 % 10173.36 % 657.5 % 2258.27 %
Operating Cash Flow Sales Ratio TTM -1515.25 % 46.89 % 35.84 % 35.02 % -23.48 % -45.52 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.05 % 64.29 % 92.69 % 83.01 % 129.82 % 122.67 %
Cash Flow Coverage Ratios TTM - 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Price To Free Cash Flows Ratio TTM -0.03 54.76 31.31 25 -61.54 -10.81
Price To Operating Cash Flows Ratio TTM -0.1 36.23 28.96 20.49 -79.67 -13.19
Price Cash Flow Ratio TTM -0.1 36.23 28.96 20.49 -79.67 -13.19
Income Statement (TTM)
BLCM NVO VRTX REGN SGEN MRNA
Revenue $0B $232.26B $9.84B $13.12B $1.96B $6.75B
Gross Profit $0B $196.5B $8.58B $11.3B $1.55B $2.06B
Gross Profit Ratio 100% 84.6% 87.17% 86.16% 79.1% 30.52%
EBITDA $-0.03B $112.94B $3.93B $5.13B $-0.62B $-3.21B
Net Income $-0.02B $83.68B $3.62B $3.95B $-0.61B $-4.71B
EPS Diluted -0.81 18.62 13.89 34.77 -3.3 -12.34
Balance Sheet (MRQ)
BLCM NVO VRTX REGN SGEN MRNA
Long Term Debt $0B $20.53B $0.72B $2.7B $0.04B $1.22B
Total Liabilities $0.02B $207.93B $5.15B $7.11B $0.87B $4.57B
Total Equity $0B $106.56B $17.58B $25.97B $2.8B $13.85B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $4.68B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $1.24B
Total Assets $0.02B $314.49B $22.73B $33.08B $3.67B $18.43B
Cash Flow Statement (TTM)
BLCM NVO VRTX REGN SGEN MRNA
Net Income $-0.02B $83.68B $3.62B $3.95B $-0.61B $-4.71B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $0.75B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.03B $108.91B $3.54B $4.59B $-0.45B $-3.12B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.71B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.85
ABCL AbCellera Biologics Inc. 3.855
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 3.44
ABIO ARCA biopharma, Inc. 3.4575
ABOS Acumen Pharmaceuticals, Inc. 3.175
ABSI Absci Corporation 4.74
ABUS Arbutus Biopharma Corporation 2.77
ABVC ABVC BioPharma, Inc. 1.4001
ABVX Abivax SA American Depositary Shares 15.48
ACAD ACADIA Pharmaceuticals Inc. 17.1
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.59
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.7601
ACHV Achieve Life Sciences, Inc. 4.6
ACIU AC Immune SA 2.41
ACLX Arcellx, Inc. 51.01
ACRV Acrivon Therapeutics, Inc. Common Stock 10.015
ACST Acasti Pharma Inc. 2.735
ETFs With Exposure to BLCM
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 112.055
Unlock